-
disease with the
exception of drug-induced parkinsonism. "Levodopa". "
Madopar Product Information". Medsinfo. 8 July 2019.
Retrieved 2
September 2024...
-
biologically inactive. l-DOPA (Levodopa; Sinemet, Parcopa, Atamet, Stalevo,
Madopar, Prolopa, etc.) l-DOPS (Droxidopa)
Methyldopa (Aldomet, Apo-Methyldopa...
-
combining L-DOPA with
benserazide was
marketed under the
brand name of
Madopar.
Independent work was
carried out by
Victor Lotti at
Merck in West Point...
-
combination with L-DOPA (levodopa) as co-beneldopa (BAN),
under the
brand names Madopar in the UK and
Prolopa in Canada, both made by Roche.
Benserazide is not...
- (dextrodopa) L-DOPA (levodopa;
trade names Sinemet, Pharmacopa, Atamet, Stalevo,
Madopar, Prolopa, etc.) L-DOPS (droxidopa)
Dopamine (Intropan, Inovan, Revivan...
-
haematological malignancies), non-Hodgkin
lymphomas and
rheumatoid arthritis.
Madopar/Prolopa ([[levodopa benserazide), for Parkinson's disease.
Mircera (methoxy...
- Corporation) or with a
benserazide (combination
medicines are
branded Madopar or Prolopa), to
prevent the
peripheral synthesis of
dopamine from levodopa)...
-
cardiovascular risk ****ociated with high
peripheral dopamine.
Benserazide (
Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc.)
Carbidopa (Lodosyn...
- (1985). "Increased life
expectancy resulting from
addition of L-deprenyl to
Madopar treatment in Parkinson's disease: a
longterm study". J
Neural Transm. 64...
-
treated with
neuroleptic drugs: a double-blind cross-over
trial with
Madopar and placebo". Psychopharmacologia. 44 (1): 105–10. doi:10.1007/bf00421193...
